Why does nanoparticle-based light scattering matter for exosome quantification?

Gold nanoparticle-conjugated antibodies enhance light scattering from captured exosomes, enabling their visualization as bright spots under dark-field microscopy. This signal amplification allows specific exosome detection in complex biofluids without fluorescent labels. The method supports quantitative analysis by correlating spot intensity or count with exosome concentration.

How does antibody immobilization on immunoassay slides support target validation?

Capture antibodies are immobilized on protein A/G-treated slides to bind specific exosome surface markers, enabling selective isolation from serum. This step ensures that only target-specific exosomes are retained for downstream detection. The approach supports target validation by confirming the presence and abundance of disease-associated exosome populations.

What quantitative measurements enable exosome enumeration in this workflow?

Exosomes are quantified by counting bright spots generated from gold nanoparticle scattering under dark-field microscopy. Each spot corresponds to a single exosome bound to the slide via antibody-nanoparticle complexes. The method provides a direct, label-free readout for exosome concentration in microliter-scale biofluid samples.

Why are replication and washing steps critical for assay reliability?

Multiple washing steps remove unbound antibodies and reduce nonspecific binding, ensuring that only specifically captured exosomes contribute to the signal. Eight replicates per sample improve statistical confidence and account for well-to-well variability. These steps are essential for reproducible exosome quantification across experimental conditions.

What statistical analysis is required before implementing this assay in biomarker studies?

Implementation requires baseline signal normalization, replicate averaging, and threshold setting for positive exosome detection. Statistical comparison across conditions depends on spot count or intensity distributions from control and treatment groups. The method supports parametric or non-parametric tests based on replicate data quality and distribution assumptions.